Vita

Prof. Dr. Anke Reinacher-Schick

Chefärztin

Hämatologie, Onkologie und Palliativmedizin

0234/509-3591

Wissenschaftlicher und beruflicher Werdegang

2017

Forschungsschwerpunkte:

  • Pankreaskarzinom, Kolonkarzinom
  • Translationale Forschung
  • Ethik in der Onkologie, Arzt-Patienten-Kommunikation
Februar 2016

Chefärztin der Abteilung für Hämatologie, Onkologie und Palliativmedizin
Katholisches Klinikum Bochum, St. Josef-Hospital, Universitätsklinik der Ruhr-Universität Bochum

September 2015

Anerkennung zum Führen der Zusatzbezeichnung Labordiagnostik-fachgebunden

November 2013

Berufung auf eine W2-Professur
für Integrierte Onkologie der Ruhr-Universität Bochum

Februar 2013

Leitende Ärztin der Abteilung für Hämatologie und Onkologie
Katholisches Klinikum Bochum, St. Josef-Hospital, Medizinische Klinik I
Universitätsklinik der Ruhr-Universität Bochum

Januar 2013

Anerkennung zum Führen der Zusatzbezeichnung Palliativmedizin

Februar 2012

Berufung auf eine W2-Professur
für Gastrointestinale Onkologie der Ruhr-Universität Bochum

Juni 2004

Oberärztin (ab 2010 Personalverantwortliche Oberärztin)
der Medizinischen Universitätsklinik der Ruhr-Universität Bochum, Knappschaftskrankenhaus, Direktor: Prof. Dr. med. W. Schmiegel

2001-2003
1994-1998

Wissenschaftliche Mitarbeiterin/Assistenzärztin in der Weiterbildung
der Medizinischen Universitätsklinik der Ruhr-Universität Bochum, Knappschaftskrankenhaus, Direktor: Prof. Dr. med. W. Schmiegel

1998-2000

Postgraduiertenstipendiatin der Dr. Mildred Scheel Stiftung für Krebsforschung
am Department of Cellular Biochemistry and Biophysics, Memorial Sloan-Kettering Cancer Center, New York, USA

 

Mitgliedschaft in Fachgesellschaften

  • Deutsche Krebsgesellschaft e.V.
    • seit 1996 als Mitglied
    • seit 1996 als Mitglied der Arbeitsgemeinschaft experimentelle Krebsforschung (AEK)
    • seit 2006 als Mitglied der Arbeitsgemeinschaft Internistische Onkologie (AIO)
    • seit 2010 als Sprecher Leitgruppe Translationale Forschung
    • seit 2016 als Sprecher Leitgruppe kolorektales Karzinom
  • Deutsche Gesellschaft für Verdauungs- und Stoffwechselerkrankungen (DGVS)
    • seit 2007 als Mitglied
  • Deutsche Krebshilfe e.V.
    • seit 2017 berufenes Mitglied im Fachausschuss „Versorgungsmaßnahmen und –forschung mit gesundheits-/strukturpolitischer Ausrichtung“ 

Wissenschaftliche Publikationen

Schneider-Gold C, Reinacher-Schick A, Ellrichmann G, Gold R.
Bortezomib in severe MuSK-antibody positive myasthenia gravis: first clinical experience.
Ther Adv Neurol Disord. 2017 Oct;10(10):339-341.

Pitarokoili K, Yoon, MS, Kröger I, Reinacher-Schick A, Gold R, Schneider-Gold C.
Severe refractory CIDP: a case series of 10 patients treated with bortezomib.
J Neurol. 2017 Aug 23.

Herbst A, Vdovin N, Gacesa S, Philipp A, Nagel D, Holdt LM, Op den Winkel M, Heinemann V, Stieber P, Graeven U, Reinacher-Schick A, Arnold D, Ricard I, Mansmann U, Hegewisch-Becker S, Kolligs FT.
Methylated free-circulating HPP1 DNA is an early response marker in patients with metastatic colorectal cancer.
Int J Cancer. 2017 May 1;140(9):2134-2144.

Schmiegel W, Scott RJ, Dooley S, Lewis W, Meldrum CJ, Pockney P, Draganic B, Smith S, Hewitt C, Philimore H, Lucas A, Shi E, Namdarian K, Chan T, Acosta D, Ping-Chang S, Tannapfel A, Reinacher-Schick A, Uhl W, Teschendorf C, Wolters H, Stern J, Viebahn R, Friess H, Janssen KP, Nitsche U, Slotta-Huspenina J, Pohl M, Vangala D, Baraniskin A, Dockhorn-Dworniczak B, Hegewisch-Becker S, Ronga P, Edelstein DL, Jones FS, Hahn S, Fox SB
Blood-based detection of RAS mutations to guide anti-EGFR therapy in colorectal cancer patients: concordance of results from circulating tumor DNA and tissue-based RAS testing.
Mol Oncol. 2017 Feb;11(2):208-219.

Quidde J, Hegewisch-Becker S, Graeven U, Lerchenmüller CA, Killing B, Depenbusch R, Steffens CC, Lange T, Dietrich G, Stoehlmacher J, Reinacher A, Tannapfel A, Trarbach T, Marschner N, Schmoll HJ, Hinke A, Al-Batran SEW, Arnold D
Qualitiy of life in assessment in patients with metastatic colorectal cancer recieving maintenance therapy after first-line induction treatment: a preplanned analysis of the phase III AIO KRK 0207 trial.
Ann Oncol. 2016 Dec; 27(12):2203-2210

Behrendt V, Krogias C, Reinacher-Schick A, Gold R, Kleiter I
Bortezomib Treatment for Patients With Anti-N-Methyl-d-Aspartate Receptor Encephalitis.
JAMA Neurol. 2016 Oct 1;73(10):1251-1253

Faissner S, Lukas C, Reinacher-Schick A, Tannapfel A, Gold R, Kleiter I
Amphiphysin-positive paraneoplastic myelitis and stiff-person syndrome.
Neurol Neuroimmunol Neuroinflamm. 2016 Sep 28;3(6):e285. eCollection 2016 Dec.

Modest DP, Ricard I, Heinemann V, Hegewisch-Becker S, Schmiegel W, Porschen R, Stinzing S, Graeven U, Arnold D, von Weikersthal LF, Giessen-Jung C, Stahler A, Schmoll HJ, Jung A, Kirchner T, Tannapfel A, Reinacher-Schick A
Outcome according to KRAS-, NRAS- ans BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group.
Ann Oncol. 2016 Sep;27(9):1746-53.

Lorenzen S, Arnold D, Fottner C, Leichsenring J, Moehler M, Seufferlein T, Vogel A, Weber MM, Reinacher-Schick A.
[ASCO-update 2015 - highlights of the 51. meeting of the american society of clinical oncology/ASCO 2015].
Z Gastroenterol. 2016 Feb;54(2):167-72. doi: 10.1055/s-0041-111632. Epub 2016 Feb 8. German.

Schneider R, Schneider C, Büttner R, Reinacher-Schick A, Tannapfel A, Fürst A, Rüschoff J, Jakobeit C, Royer-Pokora B, Möslein G
Colorectal Carcinoma with Suspected Lynch Syndrome: A Multidisciplinary Algorithm
Zentralbl Chir. 2015 Dec;140(6):591-9

Höffken N, Leichsenring J, Reinacher-Schick A
Clinically relevant, gender-specific differences in colorectal carcinoma (CRC)
Z Gastroenterol. 2015 Aug;53(8):782-8

Hegewisch-Becker S, Graeven U, Lerchenmüller CA, Killing B, Depenbusch R, Steffens CC,  Al-Batran SE, Lange T, Dietrich G, Stoehlmacher J, Tannapfel A, Reinacher-Schick A, Quidde J, Trarbach T, Hinke A, Schmoll HJ, Arnold D
Maintenance strategies after initial first-line oxaliplatin/fluoropyrimidine/bevacizumab for patients with metastatic colorectal cancer: AIO 0207, a randomized, open-label, phase 3 trial.
Lancet Oncol. 2015 Oct;16(13):1355-69

Haas M, Boeck SH, Waldschmidt D, Reinacher-Schick A, Freiberg-Richter J, Seufferlein T, Kanzler S, Mahlberg R, Siveke JT, Heinemann V
ACCEPT: Afatinib as cancer therapy for exocrine pancreatic tumors - An explorative randomized phase II trial
J Clin Oncol. 2015;33S(15)

Bolz J, Meves SH, Kara K, Reinacher-Schick A, Gold R, Krogias C.
Multiple cerebral infarctions in a young patient with heroin-induced hypereosinophilic syndrome.
J Neurol Sci. 2015 Sep 15;356(1-2):193-5; Int J. Stroke 2015 10 2:402-402

Nöpel-Dünnebacke S, Schulmann K, Reinacher-Schick A, Porschen R, Schmiegel W, Tannapfel A, Graeven U.
Prognostic value of microsatellite instability and p53 expression in metastatic colorectal cancer treated with oxaliplatin and fluoropyrimidine-based chemotherapy.
Z Gastroenterol. 2014 Dec;52(12):1394-401.

El-Mashtoly SF, Petersen D, Yosef HK, Mosig A, Reinacher-Schick A, Kötting C, Gerwert K.
Label-free imaging of drug distribution and metabolism in colon cancer cells by Raman microscopy.
Analyst. 2014 Mar 7;139(5):1155-61.

Leichsenring J, Koppelle A, Reinacher-Schick A.
Colorectal Cancer: Personalized Therapy
Gastrointest Tumors, 2014 May;1(4):209-20

Stein A, Arnold D, Thuss-Patience PC, Moehler M, Grothe W, Seufferlein T, Reinacher-Schick A, Geissler M, Hofheinz RD, Schmoll HJ.
Docetaxel, oxaliplatin and capecitabine (TEX regimen) in patients with metastatic gastric or gastro-esophageal cancer: results of a multicenter phase I/II study.
Acta Oncol. 2014 Mar;53(3):392-8.

Kähler G, Reinacher-Schick A
Colorectal Adenoma - Resection Techniques and Surveillance
Viszeralmedizin. 2014 Feb;30(1):8-9

Giessen C, Graeven U, Laubender RP, Modest DP, Schulz C, Porschen R, Schmiegel W, Reinacher-Schick A, Hegewisch-Becker S, Stintzing S, Heinemann V.
Prognostic factors for 60-day mortality in first-line treatment of metastatic colorectal cancer (mCRC): individual patient analysis of four randomised, controlled trials by the AIO colorectal cancer study group.
Ann Oncol. 2013 Dec;24(12):3051-5.

Brand L, Munding J, Pox CP, Ziebarth W, Reiser M, Hüppe D, Schmiegel W, Reinacher-Schick A, Tannapfel A.
ß-Catenin, Cox-2 and p53 immunostaining in colorectal adenomas to predict recurrence after endoscopic polypectomy.
Int J Colorectal Dis. 2013 Aug;28(8):1091-8.

Pox C, Aretz S, Bischoff SC, Graeven U, Hass M, Heußner P, Hohenberger W, Holstege A, Hübner J, Kolligs F, Kreis M, Lux P, Ockenga J, Porschen R, Post S, Rahner N, Reinacher-Schick A, Riemann JF, Sauer R, Sieg A, Scheppach W, Schmitt W, Schmoll HJ, Schulmann K, Tannapfel A, Schmiegel W.
S3-guideline colorectal cancer version 1.0.
Z Gastroenterol. 2013 Aug;51(8):753-854.

Schmiegel W, Reinacher-Schick A, Arnold D, Kubicka S, Freier W, Dietrich G, Geißler M, Hegewisch-Becker S, Tannapfel A, Pohl M, Hinke A, Schmoll HJ, Graeven U.
Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group.
Ann Oncol. 2013 Jun;24(6):1580-7.

Seufferlein T, Porzner M, Becker T, Budach V, Ceyhan G, Esposito I, Fietkau R, Follmann M, Friess H, Galle P, Geissler M, Glanemann M, Gress T, Heinemann V, Hohenberger W, Hopt U, Izbicki J, Klar E, Kleeff J, Kopp I, Kullmann F, Langer T, Langrehr J, Lerch M, Löhr M, Lüttges J, Lutz M, Mayerle J, Michl P, Möller P, Molls M, Münter M, Nothacker M, Oettle H, Post S, Reinacher-Schick A, Röcken C, Roeb E, Saeger H, Schmid R, Schmiegel W, Schoenberg M, Siveke J, Stuschke M, Tannapfel A, Uhl W, Unverzagt S, van Oorschot B, Vashist Y, Werner J, Yekebas E; Guidelines Programme Oncology AWMF; German Cancer Society eV; German Cancer Aid.
S3- Guideline exocrine pancreatic cancer.
Z Gastroenterol. 2013 Dec;51(12):1395-440

Baraniskin A, Nöpel-Dünnebacke S, Ahrens M, Jensen SG, Zöllner H, Maghnouj A, Wos A, Mayerle J, Munding J, Kost D, Reinacher-Schick A, Liffers S, Schroers R, Chromik AM, Meyer HE, Uhl W, Klein-Scory S, Weiss FU, Stephan C, Schwarte-Waldhoff I, Lerch MM, Tannapfel A, Schmiegel W, Andersen CL, Hahn SA.
Circulating U2 small nuclear RNA fragments as a novel diagnostic biomarker for pancreatic and colorectal adenocarcinoma.
Int J Cancer. 2013 Jan 15;132(2):E48-57.

Pox C, Schmiegel W, Reinacher-Schick A.
Colorectal carcinoma: what's new.
Dtsch Med Wochenschr. 2012 Dec;137(49):2577-80.

Reinacher-Schick A, Schulmann K, Modest D, Bruns N, Graeven U, Jaworska M, Greil R, Porschen R, Arnold D, Schmiegel W and Tannapfel A.
Effect of KRAS codon13 mutations in patients with advanced colorectal cancer (advanced CRC) under oxaliplatin containing chemotherapy. Results from a translational study of the AIO colorectal study group.
BMC Cancer. 2012 Aug 9; 12:349.

Modest DP, Reinacher-Schick A, Stintzing S, Giessen C, Tannapfel A, Laubender RP, Brodowicz T, Knittelfelder R, Vrbanec D, Schmiegel W, Heinemann V, Zielinski CC.
Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D-mutated metastatic colorectal cancer: a pooled analysis.
Anticancer Drugs. 2012 Juli; 23(6):666-673.

Harder J, Ihorst G, Heinemann V, Hofheinz R, Moehler M, Buechler P, Kloeppel G, Röcken C, Bitzer M, Boeck S, Endlicher E, Reinacher-Schick A, Schmoor C, Geissler M.
Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer.
Br J Cancer. 2012 Mar 13;106(6):1033-8.

Baraniskin A, Birkenkamp-Demtroder K, Maghnouj A, Zöllner H, Munding J, Klein-Scory S, Reinacher-Schick A, Schwarte-Waldhoff I, Schmiegel W, Hahn SA.
MiR-30a-5p suppresses tumor growth in colon carcinoma by targeting DTL.
Carcinogenesis. 2012 Apr;33(4):732-9.

Matthias P.A. Ebert, Marc Tänzer, Benjamin Balluff, Elke Burgermeister, Antje Karen Kretzschmar, David J. Hughes, Reimo Tetzner, Catherine Lofton-Day, Robert Rosenberg, Anke C. Reinacher-Schick, Karsten Schulmann, Andrea Tannapfel, Ralf Hofheinz, Christoph Röcken, Gisela Keller, Rupert Langer, Katja Specht, Rainer Porschen, Jan Stöhlmacher-Williams, Tibor Schuster, Philipp Ströbel, Roland M. Schmid.
TFAP2E/DKK4 and Chemoresistance in Colorectal Cancer.
N Engl J Med, 2012 Jan 5;366(1):44-53.

Munding J, Ziebarth W, Pox CP, Ladigan S, Reiser M, Hüppe D, Brand L, Schmiegel W, Tannapfel A, Reinacher-Schick AC.
The influence of 5-Aminosalicylic acid on the progression of colorectal adenomas via the ß-catenin signaling pathway.
Carcinogenesis. 2012 Mar;33(3):637-43

Kampfenkel T, Tischoff I, Bonhag H, Eckardt M, Schmiegel W, Tannapfel A, Reinacher-Schick A, Viebahn R.
Chemotherapy-associated steatohepatitis in patients with colorectal cancer and surgery on hepatic metastasis: clinical validation of a histopathological scoring system and preoperative risk assessment.
Z Gastroenterol. 2011 Oct;49(10):1407-11.

Pohl M, Werner N, Munding J, Tannapfel A, Graeven U, Nickenig G, Schmiegel W, Reinacher-Schick A.
Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature.
Z Gastroenterol. 2011 Oct;49(10):1398-406.

Baraniskin A, Munding J, Schulmann K, Meier D, Porschen R, Arkenau HT, Graeven U, Schmiegel W, Tannapfel A, Reinacher-Schick A.
Prognostic value of reduced SMAD4 expression in patients with metastatic colorectal cancer under oxaliplatin-containing chemotherapy: a translational study of the AIO colorectal study group.
Clin Colorectal Cancer. 2011;10(1):24-9.

Baraniskin A, Kuhnhenn J, Schlegel U, Chan A, Deckert M, Gold R, Maghnouj A, Zöllner H, Reinacher-Schick A, Schmiegel W, Hahn SA, Schroers R
Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system.
Blood. 2011;117(11):3140-6.

Goede V, Coutelle O, Neuneier J, Reinacher-Schick A, Schnell R, Koslowsky T, Weihrauch M, Crèmer B, Kashkar H, Odenthal M, Schmiegel W, Hallek M, Hacker U
Identification of Serum Angiopoietin-2 as a Biomarker for Clinical Outcome of Colorectal Cancer Patients Treated with Bevacizumab-Containing Therapy
Br J Cancer, 2010;103(9):1407-14

Michael Pohl, Yvonne Radacz, Nicole Pawlik, Anna Schoeneck, Stephan E. Baldus, Johanna Munding, Wolff Schmiegel, Irmgard Schwarte-Waldholff and Anke Reinacher-Schick
Smad4 mediates mesenchymal-epithelial reversion in SW480 colon carcinoma cells
Anticancer Res., 2010;30:2603-2614

Wieser M, Sauerland S, Arnold D, Schmiegel W, Reinacher-Schick A
Peri-operative chemotherapy for the treatment of resectable liver metastases from colorectal cancer: A systematic review and meta-analysis of randomized trials
BMC Cancer, 2010;10:309

Weiß JV, Klein-Scory S, Kübler S, Reinacher-Schick A, Stricker I, Schmiegel W, Schwarte-Waldhoff I
Soluble E-cadherin as a serum biomarker candidate: Elevated levels in late stage colorectal carcinoma patients and in FAP.
Int J Cancer. 2010 May 5. Feb 25;10:70.

Trarbach T, Reinacher-Schick A, Hegewisch-Becker S, Vanhoefer U, Frieling T, Lehnert L, Schmiegel W, Graeven U.
Gefitinib in combination with capecitabine as second-line therapy in patients with advanced colorectal cancer (aCRC): a phase I/II study of the arbeitsgemeinschaft internistische onkologie (AIO).
Onkologie. 2010;33(3):89-93.

Klein-Scory S, Kubler S, Diehl H, Eilert-Micus C, Reinacher-Schick A, Stuhler K, Warscheid B, Meyer HE, Schmiegel W, Schwarte-Waldhoff I.
Immunoscreening of the extracellular proteome of colorectal cancer cells.
BMC Cancer. 2010 Feb 25;10(1):70.

Salloch H*, Reinacher-Schick A*, Schulmann K, Pox C, Willert J, Tannapfel A, Heringlake S, Goecke TO, Aretz S, Stemmler S, Schmiegel W.
Truncating mutations in Peutz-Jeghers syndrome are associated with more polyps, surgical interventions and cancers.
Int J Colorectal Dis. 2010 Jan;25(1):97-107.
(*these authors contributed equally to the work and should be considered first authors)